Here we go again?

Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not meet its primary endpoint in a Phase 2 study. But the company said it slowed …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844